Inhibrx Biosciences, Inc.
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and a…
$89.83
-$0.67 (-0.74%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-10386.54% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 550.0% YoY with margins expanding 155337.5pp.
Negative free cash flow of -$130M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$1M
▲ +550.0% YoY
Net Income (TTM)
-$138M
▼ -108.3% YoY
Op. Margin
-10386.54%
▲ +155337.5pp YoY
ROIC
-65.01%
▲ +49.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$132M
▲ +34.1% YoY
Op. Cash Flow (TTM)
-$132M
▲ +33.2% YoY
Net Debt
$48M
Cash & Equiv.
$133M
Continue Research
SourceComputed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Inhibrx Biosciences (INBX) overvalued?
Inhibrx Biosciences (INBX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Inhibrx Biosciences scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Inhibrx Biosciences a high-quality business?+
Inhibrx Biosciences scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -10,386.5% operating margin and a -65.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Inhibrx Biosciences a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh INBX's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Biological Products, (No Diagnostic Substances)
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.